Compare Cassava Sciences Inc (FLNA) vs Halliburton Company (HAL) Price & Performance

FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.

Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.

Halliburton (HAL) trades at $34.99, down 1.21% on the day, with a bullish technical signal from moving averages and recent contract wins boosting sentiment. The company shows solid profitability with a 6.95% net income margin and 14.56% ROE, though 2025 revenue dipped to $22.18B. Earnings have beaten estimates for three consecutive quarters, with Q2 2026 results pending. Cash flow trends are mixed, with 2025 net cash flow negative at -$412M despite strong operational cash generation.

The outlook remains positive with a consensus price target of $44.78, implying 28% upside, supported by 71% analyst buy ratings. Key risks include oil price volatility and execution challenges from new contracts. The stock's current valuation at a P/E of 19.48 appears reasonable relative to growth prospects, but investors should monitor debt levels and global energy demand shifts.